← Representative Cases

US market launch readiness after regulatory approval

Situation

A small molecule product was approaching first-to-market US regulatory approval within a highly controlled GMP/GxP manufacturing environment.

Challenge

Key stakeholders requested commercial launch readiness within four weeks. Typical European implementation timelines for first-time-right packaging and serialization activities were approximately twelve weeks, with any deviation adding another full cycle. Initial cross-functional discussions largely centered around “cannot be done” versus “must be done”, creating risk of organizational deadlock.

Approach

Recognizing that internal experience limitations did not necessarily define the true feasibility window, I strengthened the team with dedicated project management support and shifted the discussion from constraints to scenario-based execution planning.
Together with Regulatory Affairs, Supply Chain, QA and Marketing, we prepared artwork and launch activities in parallel with the regulatory process. Packaging materials were ordered at controlled financial risk, intermediate product was pre-positioned in the US to eliminate customs delays, and both US and European fallback execution scenarios were developed to protect launch continuity under multiple approval outcomes.

Result

Following regulatory approval without required artwork modifications, packaging and serialization activities started immediately. Released commercial product was successfully shipped within one week after PDUFA approval, enabling uninterrupted market entry and seamless patient transition from early access programs to commercial supply.

Leadership Dimension

Created alignment and execution focus across functions operating under significant time pressure and regulatory scrutiny. The project also strengthened internal capabilities in project management, launch execution, risk management and international distribution readiness.